Drug intelligence / Profile preview

STN-002

Development stage: Preclinical
Lead developer: Synthetic Design Lab
Modality: Recombinant Proteins and Enzymes

Overview

STN-002 is a preclinical-stage therapeutic candidate being developed by Synthetic Design Lab for the treatment of obesity and addiction. The drug is developed using the company's synthetic enzyme engineering platform, which focuses on designing novel enzymes to modulate metabolic pathways. STN-002 is currently in the discovery and preclinical phase, with its primary mechanism involving metabolic regulation to address the underlying biology of weight management and substance use disorders.

Beyond the preview

Go deeper on STN-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STN-002.

Explore the full profile